Neoantigen DNA vaccine + Durvalumab
Phase 2Active 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Extensive-stage Small Cell Lung Cancer
Conditions
Extensive-stage Small Cell Lung Cancer
Trial Timeline
Mar 30, 2022 → Sep 30, 2029
NCT ID
NCT04397003About Neoantigen DNA vaccine + Durvalumab
Neoantigen DNA vaccine + Durvalumab is a phase 2 stage product being developed by AstraZeneca for Extensive-stage Small Cell Lung Cancer. The current trial status is active. This product is registered under clinical trial identifier NCT04397003. Target conditions include Extensive-stage Small Cell Lung Cancer.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04397003 | Phase 2 | Active |
Competing Products
20 competing products in Extensive-stage Small Cell Lung Cancer